Lancet respir med:兰迪洛尔用于治疗脓毒症相关心动过速

2020-04-01 MedSci原创 MedSci原创

兰迪洛尔可治疗脓毒症相关的心动过速,且耐受性良好

脓毒症或脓毒性休克患者发生心动过速和房颤导致不良预后风险增加。近日研究人员考察了超短效β受体阻滞剂兰地洛尔治疗脓毒症相关心律失常的有效性和安全性。
 
研究人员在日本54家医院开展,ICU接受常规治疗的脓毒症患者参与研究,患者出现快速心律失常,患者在给予儿茶酚胺,使平均动脉压保持在65毫米汞柱或以上至少1小时,心率保持在每分钟100次或以上(bpm)至少10分钟,诊断为心室颤动、心房扑动或窦性心动过速。上述患者随机接受常规脓毒症治疗(对照组)或常规脓毒症治疗加兰地洛尔 (兰地洛尔组)治疗。分组后2小时内,以每分钟1μg/kg的初始剂量静脉注射盐酸兰地洛尔,剂量可根据研究方案增加至最高每分钟20μg/kg。常规治疗包括呼吸和液体复苏、抗菌药物和儿茶酚胺。研究的主要结果是随机分组后24小时心率为60-94 bpm的患者比例。
 
151名患者参与研究,76名接受兰地洛尔,75名患者为对照。随机分组后24小时,兰地洛尔组的心率为60-94 bpm的患者比例明显高于对照组(55%[41/75 ]vs 33%[25/75]),组间差异为23.1%。兰地洛尔组77例患者中49例(64%)和对照组74例患者中44例(59%)出现不良事件,兰地洛尔组77例患者中有9例(12%)和对照组74例患者中8例(11%)观察到严重不良事件(包括导致死亡的不良事件)。在77例患者中有5例(6%)发生了与兰迪洛尔有关的严重不良事件,包括3例血压下降(4%),心脏骤停,心率下降,射血分数下降各1例(1%)。
 
研究认为,兰迪洛尔可治疗脓毒症相关的心动过速,且耐受性良好。
 
原始出处:
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1949633, encodeId=1c1819496337d, content=<a href='/topic/show?id=1616299e151' target=_blank style='color:#2F92EE;'>#兰迪洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29971, encryptionId=1616299e151, topicName=兰迪洛尔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Mon Mar 15 02:39:00 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830563, encodeId=bd93183056346, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Oct 30 13:39:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471126, encodeId=08a914e1126cc, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Fri Apr 03 10:39:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610400, encodeId=837216104001a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 03 10:39:00 CST 2020, time=2020-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1949633, encodeId=1c1819496337d, content=<a href='/topic/show?id=1616299e151' target=_blank style='color:#2F92EE;'>#兰迪洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29971, encryptionId=1616299e151, topicName=兰迪洛尔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Mon Mar 15 02:39:00 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830563, encodeId=bd93183056346, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Oct 30 13:39:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471126, encodeId=08a914e1126cc, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Fri Apr 03 10:39:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610400, encodeId=837216104001a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 03 10:39:00 CST 2020, time=2020-04-03, status=1, ipAttribution=)]
    2020-10-30 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1949633, encodeId=1c1819496337d, content=<a href='/topic/show?id=1616299e151' target=_blank style='color:#2F92EE;'>#兰迪洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29971, encryptionId=1616299e151, topicName=兰迪洛尔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Mon Mar 15 02:39:00 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830563, encodeId=bd93183056346, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Oct 30 13:39:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471126, encodeId=08a914e1126cc, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Fri Apr 03 10:39:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610400, encodeId=837216104001a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 03 10:39:00 CST 2020, time=2020-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1949633, encodeId=1c1819496337d, content=<a href='/topic/show?id=1616299e151' target=_blank style='color:#2F92EE;'>#兰迪洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29971, encryptionId=1616299e151, topicName=兰迪洛尔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Mon Mar 15 02:39:00 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830563, encodeId=bd93183056346, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Oct 30 13:39:00 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471126, encodeId=08a914e1126cc, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Fri Apr 03 10:39:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610400, encodeId=837216104001a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 03 10:39:00 CST 2020, time=2020-04-03, status=1, ipAttribution=)]
    2020-04-03 智慧医人

相关资讯

Chest:脓毒症初始治疗期间的输液量应该多还是少?

在这项系统综述中,研究人员发现证据数量少和质量非常低,不足以支持对败血症成人进行静脉输液治疗量的决定。

Anesthesiology:静脉注射重组高密度脂蛋白可改善脓毒症小鼠的存活率

高密度脂蛋白具有多效性,包括抗炎、抗凋亡和脂多糖中和特性。本研究旨在评价静脉注射重组高密度脂蛋白(CSL-111)对不同脓毒症模型的影响。

Intens Care Med:脓毒症幸存者再住院的发生率和危险因素

由此可见,败血症幸存者再住院事件很常见,五分之一的再住院事件发生败血症入院后的30天内。脓毒症患者入院时的一般特征和脓毒症特异性特征是再住院的危险因素。

Lancet:全球脓毒症负担研究

尽管年龄标准化的发病率和死亡率不断下降,但脓毒症仍然是威胁全世界健康的主要原因,特别是撒哈拉以南非洲负担尤其沉重

Crit Care:预测脓毒症危重患者的临床轨迹

由此可见,该预测模型可估计败血症期间疾病严重程度的每日演变,最终可能支持临床医生做出更明智的治疗决策,并可用于评估预后生物标志物或在试验过程中对新型败血症疗法进行计算机模拟设计。

Blood:Fc-修饰型抗PF4-NET复合物单克隆抗体KKO明显改善脓毒症预后

脓毒症是由感染引起的全身炎症反应综合征,特征是炎症导致多器官系统功能障碍。发病率和病死率高,需要改善其治疗方法。中性粒细胞在脓毒症过程中具有至关重要的作用,它释放由组蛋白和有毒抗菌蛋白组成的胞外中性粒细胞陷阱(NETs)来捕捉病原体,但与此同时也会损伤宿主组织。发病时,患者往往已有很重的NET负荷,导致多器官受损。因此,发病时再予以抑制NET释放的干预措施,在预防NET相关损伤方面可能是无效的。加